CD4 and neoplasm: Moreover, a significant (p < 0.05) increase in the CD4+ and CD8+ T cells of tumor-infiltrated and lymph node lymphocytes in the TEXomiR group compared with the PBS-treated group was demonstrated (Figure 7).